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rently employed and identify opportunities for future research.METHODS: A com-
prehensive literature review of reference databases, conference abstracts, journals
and medical societies’ websites was performed. Publications reporting practice
management efficiency measures within ambulatory oncology practices and infu-
sion centers located in the United States were included. Search was limited to
English-language articles published between 2007 and 2010. All publication types
except continuing medical education materials and letters to the editor were ac-
cepted. Evidence quality was assessed with the Completeness of Reporting index
(CORE-14) instrument. RESULTS: Forty-seven references were accepted for inclu-
sion. Efficiency strategieswere classified into 7 distinct categories, each reported at
a similar frequency in the literature. Within and across these categories, common
themeswere standardization of care, use of best practices, and alignment between
quality and profitability initiatives. Most publications were recommendations
without a study design type (64%) and/or did not report quantifiable outcome data
(74%). Additionally, 21 publications did not define the practice type included, while
the remaining articles identified 12 different practice types. Consequently, appli-
cability is limited, since outcomes cannot be associated with a particular practice
type. Thirty-four publications were assigned a CORE-14 score of 0, indicating they
did not meet any criteria for methodological quality (mean score, 1.84).
CONCLUSIONS: Numerous efficiency methods are being touted in the literature,
but there is limited definitive data on the successfulness of these techniques. Fur-
ther research, of a high methodological caliber, is needed to support informed
decisions. Specifically, registries, surveys, and economic analyses would empower
oncologists and other oncology professionals with practical strategies to concur-
rently improve quality while maintaining profitability.
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A REVIEW OF EXPANDED ACCESS PROGRAMS (EAP) AND THEIR
CONSIDERATION BY HEALTH PLAN DECISION-MAKERS IN THE UNITED STATES
Khurdayan V, Rizzo M, Darity A, Mun D
Double Helix Consulting, New York, NY, USA
OBJECTIVES: After failing approved treatments, patients may receive investiga-
tional therapies through participation in a clinical trial or an expanded access
program (EAP). EAPs were established after the FDA decided to allow patients ac-
cess to investigational drugs for treatment purposes, and since then EAPs have
been set up in various therapeutic areas including oncology and infectious dis-
eases. No analysis, however, has been completed evaluating the use and value of
EAP data to US payers.METHODS:We analyzed the impact of EAP data on the US
payer decision making process in drug formulary positioning. Using examples of
different types of drug data including EAP, payers were asked how each type af-
fected drug coverage. After reviewing these results, we assessed payers’ awareness
of EAP relative to other data types to determine future impacts of EAP. Our study
allowed us to define the key value drivers for EAP trials and construct a value
matrix to evaluate future EAP opportunities. RESULTS: Payers in the United States
had a low awareness of EAP data driven by a lack of exposure to the data type but
mostly attributed to their sole use of RCT data in formulary decisions. While most
payers agreed that EAP data has little influence on their decision making process,
they did highlight factors that make EAP data more valuable to other stakeholders
and discussed how EAP data could improve product perception. CONCLUSIONS:
Our findings suggest that payers will not change their management approach and
formulary decisions based on EAP data. Payers realize that EAP datamight bemore
representative of the real world patient population than data from RCTs; however,
RCTs will remain the gold standard data source to evaluate agents for reimburse-
ment and formulary placement.
Gastrointestinal Disorders – Clinical Outcomes Studies
PGI1
INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT
INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES
Diels J, Gavart S, Nuyts G
Janssen Pharmaceutica, Beerse, Belgium
OBJECTIVES: Conventional peginterferon-ribavirin antiviral treatment of chronic
hepatitis C virus (HCV) often leads to anemia and neutropenia. Based on US claims
data, we explored the incidence of both adverse events (AEs) and the associated
risk factors, and assessed the related erythropoietin/granulocyte colony stimulat-
ing factor (G-CSF) costs in daily clinical practice.METHODS: Commercially insured
patients with chronic HCV infection (ICD9 070.44,070.54,070.70,070.71) (all geno-
types), who initiated any combination of (peg)interferon and/or ribavirin were
identified in a large US claims database (Thomson 2006–2009). Time to first onset of
anemia and neutropenia was analyzed using Kaplan-Meier and Cox proportional
hazards regression. Anemia and neutropenia were defined based on ICD9-coding
(280-285,288) and/or prescription of erythropoietin and G-CSF. RESULTS: 3,935
chronic HCV-infected patients (mean age 51.1, 63%male) initiated HCV treatment.
86% of the patients initiated a combination of peginterferon and ribavirin. Mean
treatment duration was 245 days. Regardless of time on treatment, 32%/17% of the
cohort experienced anemia/neutropenia respectively. Age, female gender, Charl-
son co-morbidity index and liver cirrhosis were predictive for both AEs. 20.3%/
11.3% of the cohort received erythropoietin/G-CSF treatment respectively, on av-
erage for 131/126 days. Themean cost for the entire cohort tomanage both AEswas
$2,263 (erythropoietin) and $1,004 (G-CSF), which represents 12% of the overall
healthcare cost in the follow-up year for the entire cohort. Themajority of the costs
associated with AE-related treatments (58%/54%) occurred after week 24 of
therapy. CONCLUSIONS: Costs of managing anemia and neutropenia during HCV
treatment are considerable and often continued beyond 24 weeks of treatment.
New HCV treatment combinations allowing to shorten treatment up to 24 weeks,
may considerably reduce AE-related costs. This reduction may be most important
in treatment-naive genotype 1-infected patients, as the standard 48-week treat-
ment duration is longer compared with other genotypes.
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PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
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OBJECTIVES: The aim of this study was to explore the predictors of PPI dosing
regimen [once daily (QD) or twice daily (BID)] among patients with GERD.
METHODS: Using the HealthCore Integrated Research Database from 01/01/2004-
06/30/2009, GERD patients (ICD-9 codes 530.10-530.13, 530.19, 530.81, or 787.1x), 
18 years of age, having at least two PPI pharmacy claims (index date) from 01/01/
2005-06/30/2008 and continuous eligibility for 12months before and after the index
date were identified. Based on the PPI dosing regimen throughout the post-index
period, calculated as the ratio of quantity of medication dispensed/number of days
supply, GERD patients were classified as QD (ratio of 1.5) or BID (ratio of 1.5) PPI
users. Descriptive analyses were used to compare QD vs. BID PPI users and a mul-
tivariate logistic regressionwas conducted to assess independent predictors of BID
PPI use. RESULTS: This study included 248,386 GERD patients with a mean age of
52.8 (13.93) years and 56% were females. Based on the dosing regimen, 90%
(n222,759) were classified as QD and 10% (n25,627) as BID PPI users. Patients
with BID PPI dosing were significantly (all p0.0001) more likely to have Barrett’s
Esophagus (5% vs. 2%), baseline H2RA use (8.7% vs. 6.8%) and higher comorbidity
based on mean Deyo Charlson’s Comorbidity Index score (DCI) [0.89 (SD1.54) vs.
0.70 (SD1.37)]. Logistic regression results demonstrated that females [OR1.13
(95% CI1.08-1.18)], a diagnosis for Barrett’s Esophagus [OR2.08 (95% CI1.84-
2.36)], baseline H2RA [OR1.29 (95% CI1.20-1.39)] or PPI use [OR1.67 (95%
CI1.59-1.74)] and higher DCI score [OR1.09 (95%CI1.08-1.10)] were significant
(all p0.0001) predictors of BID PPI use. CONCLUSIONS: Patients who have a diag-
nosis of Barrett’s Esophagus, had baseline use of PPI or H2RA therapywere found to
be significant predictors of BID PPI dosing. Further studies understanding the dif-
ferences in clinical and economic outcomes based on PPI dosing regimen should be
undertaken.
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OBJECTIVES:The etiology of functional dyspepsia (FD) is debated. However, limited
published data exist on the associated co-morbid conditions with FD. This study
aimed to assess the odds (likelihood) of having FD based on the presence of other
objectively defined comorbid conditions.METHODS: Retrospective database anal-
ysis on a 4-year study period (2001-2004), using payroll data and adjudicated health
insurancemedical and prescription claims onmore than 300,000 employees. Study
comparisons were performed among employees with FD (ICD9 536.8x) and pro-
pensity-score-matched employees without FD (controls, matched on age, gender,
tenure with employer, marital status, race, region, salary, exempt status, and full-
time/part-time). Comorbid conditions were Specific Conditions (SC) defined by the
Agency for Healthcare Research and Quality (AHRQ). Subjects were classified as
having the condition by any claims with an ICD-9 code for the SC. The likelihood of
being in the FD cohort was modeled using logistic regression with indicator (1/0)
variables for 260 of the 261 specific AHRQ SCs (the FD-SC was not included). Odds
ratios 1.0 indicate the corresponding SC is more likely in the FD cohort, while
ratios1.0 indicate the SC is less likely to be in the FD cohort. RESULTS: The study
dataset contained 85,119 employees (1669 with FD and 83,450 matched controls
without FD). After controlling for all other AHRQ categories, the logistic regression
found that 19 specific categories weremore likely within the FD cohort, and 2 were
less likely within the FD cohort. Esophageal disorders, gastritis and duodenitis,
abdominal pain, and gout were most associated with having FD (odds ratios of 3.8,
3.7, 3.6, and 2.5, respectively). Only hypertension complications/secondary and
disorders of teeth and jaw were significantly negatively associated with FD.
CONCLUSIONS: This study identified varied comorbidities associated with FD di-
agnoses and may aid FD identification in future research.
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Wagner JS, Goren A
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OBJECTIVES: Chronic hepatitis C, in its early stages, is commonly asymptomatic,
and many patients do not seek treatment. The current study attempts to identify
the characteristics of hepatitis C patients who initiate treatment for hepatitis C.
METHODS: This study is based on data from the 2009 and 2010 waves of the US
National Health andWellness Survey (N132,478), a cross-sectional database rep-
resentative of the adult US population. Patients who reported having been diag-
nosedwith hepatitis C by a physician were included for analysis (n1279). Patients
currently, or ever, taking a prescription medication for hepatitis C (n579) were
compared with patients who never took a prescription for hepatitis C (n700).
Group membership was predicted with a logistic regression model, including age,
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gender, ethnicity, marital status, educational attainment, household income, em-
ployment status, insurance possession, body mass index, exercise and smoking
habits, alcohol use, and HIV/AIDS and hepatitis B status as predictors. RESULTS:
Mean age was similar between hepatitis C patients who had ever initiated treat-
ment (51.3 yrs, SD11.39) and thosewho had not (52.0 yrs, SD11.50). Patients who
were married (OR1.43, p.004), in possession of insurance (OR1.56, p.003), or
diagnosed with AIDS or HIV (OR1.60, p.05) were more likely to have initiated
treatment than patients without those characteristics. No other significant differ-
ences were found. CONCLUSIONS: The current findings indicate that lack of insur-
ance and lack of support from a partner are associatedwith lower odds of initiating
treatment for hepatitis C. While speculative, this suggests that lack of social sup-
port and insurance may be barriers to treatment. Patients treated for hepatitis C
may be more informed about their HIV/AIDS status, although conversely, patients
with HIV/AIDS may be more likely to initiate therapy to avoid liver-related immu-
nodeficiency complications. Further investigation is needed to help determine the
direction of causation.
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COMPARISON OF HEALTH CARE UTILIZATIONS BETWEEN PATIENTS WITH
GASTROESOPHAGEAL REFLUX DISEASE WHO SWITCHED FROM A BRANDED
PROTON PUMP INHIBITOR TO A GENERIC PROTON PUMP INHIBITOR AND VICE
VERSA
Xie L, Baser E, Wang L, Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To compare health care utilizations between patients who switched
from a branded proton pump inhibitor (PPI) to a generic PPI and vice versa.
METHODS:We conducted a retrospective database analysis using commercial en-
rollees froma largeUShealth plan fromFebruary 2008 toMarch 2010. Continuously
eligible adult patients who had gastroesophageal reflux disease (GERD) or GERD-
related conditions, and evidence of PPI use during February 2009 to September 2009
were included. The index PPI was defined as the first PPI prescribed during the
identification period. Patients who switched from a generic PPI to a branded index
PPI and patientswho switched froma branded index PPI to a generic index PPIwere
included as the two cohorts in this study. Risk adjustment was performed using
propensity score matching. We controlled for age, gender, region, GERD severity,
plan, pre-index Quan-Charlson comorbidity score (CCI), baseline DACON, and
baseline costs and utilization. RESULTS: A total of 9881 patients from each cohort
were matched after propensity score matching. During the six months after the
switch, therewere no significant differences in office visits, emergency roomvisits,
and inpatients admission rates between the two groups of switchers. Patients who
switched from a branded PPI to a generic PPI had a slightly lower rate of outpatient
visits compared to patients who switched from a generic PPI to a branded PPI
(54.67% vs. 56.23%, p0.0275). CONCLUSIONS:Although outpatient visit rates were
slightly lower for patientswho switched froma branded to a generic PPI, therewere
no significant differences in other health care utilizations such as office visits,
emergency room visits, and inpatient admissions.
Gastrointestinal Disorders – Cost Studies
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THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS
WITH HEPATITIS C VIRUS: A STATE MEDICAID PERSPECTIVE
Menzin J1, White LA1, Nichols C1, Deniz B2
1Boston Health Economics, Inc., Waltham, MA, USA, 2Vertex Pharmaceuticals Incorporated,
Cambridge, MA, USA
OBJECTIVES: Untreated chronic hepatitis C (HCV) may progress to advanced liver
disease (ALD), including decompensated cirrhosis (DC) and/or hepatocellular car-
cinoma (HCC). ALD can lead to significant clinical and economic consequences,
including liver transplantation. There are limited data on ALD-associated health-
care costs among HCV-infected patients in a Medicaid program.METHODS: Using
Florida Medicaid administrative claims data, we identified cases with HCV diagno-
sis on an inpatient or outpatient claim, or prescription HCV therapy, with an inci-
dent ALD-related diagnosis (“index event”) between 7/1/1999 and 6/30/2007. ALD-
related conditions included DC, HCC, or liver transplant procedure or history.
Patients were included if they had11months continuousMedicaid eligibility pre-
and post-index, and no enrollment in Medicare or an HMO. A one-to-one matched
control cohort of HCV cases without ALD was generated using age, sex, and race.
2009 USD per-patient-per-month (PPPM) costs were reported and compared be-
tween cases and controls usingWilcoxon rank sum tests. RESULTS: The final study
group included 1,193 cases and 1,193 matched controls (mean age: 49 years; 45%
female; 54% white, 23% black, 23% other). The majority of ALD-related diagnoses
were DC (92%), followed by HCC (6%) and liver transplant (2%). Cases with ALD had
greater comorbidity (mean Charlson score: 3.1 vs. 2.3 among controls, P.001).
All-cause inpatient resource use in the one year follow-up from incident ALD di-
agnosis was significantly greater among cases than controls (74% vs. 27%, P.001).
Mean all-cause PPPM costs (including inpatient, outpatient, pharmacy, and others)
were 3 times greater among cases with ALD than controls ($4,937 vs $1,730,
P.001). CONCLUSIONS: HCV patients with ALD had a 2.9-fold higher economic
burden in Florida Medicaid from 7/99 to 6/07 than the controls in the first year
following ALD development. Preventing or delaying ALD onset in HCV patients
could potentially help reduce this economic burden. Further study is necessary.
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OBJECTIVES: Gastroesophogeal reflux disease (GERD) is a common disease affect-
ing 10-20% of the US adult population. The objective of this study was to estimate
the prevalence of refractory GERD and associated direct medical costs using real-
world data.METHODS: Adult patients with GERD initiating a GERDmedication were
identified using theMarketScan Research Databases (2004-2009) and evaluated in the
twelve months before and after GERD medication initiation. Refractory GERD was
evaluated using an eight point scalewhere one pointwas given for each of the follow-
ing: doubling GERD medication dose (including BID), adding another GERD medica-
tion, switchingGERDmedications, GERD-related procedure receipt, GERD-related sur-
gery receipt, excess GI-related outpatient visits (2), excess GERD-related office visits
(2), or GI-related ER visits. Patients were determined to have refractory GERD if they
had 2 or more points. Annual unadjusted and multivariate adjusted GERD-related
costs (i.e., claims with a GERD diagnosis) and all-cause costs were reported in 2009
dollars for patients with and without refractory GERD. RESULTS: A total of 135,139
GERD patientswere analyzed (mean age 52.9 (SD14.5) years, 44%male). Approx-
imately one-third (31%) of patients had refractory GERD. Versus patients with non-
refractory GERD, refractory GERD patients were more likely to be female (59% vs.
55%, p0.001) and had a higher Deyo Charlson Comorbidity score after GERDmed-
ication initiation (0.78 vs. 0.56, p 0.001); average age was similar in both groups.
Compared to non-refractory GERD patients, refractory GERD patients had higher
total all-cause costs ($18,088 (SD$36,220) versus $11,044 ($22,985), p0.001) and
higher GERD-related costs ($2,022 (SD$2,236) versus $1,172 (SD$1,117), p0.001).
After controlling for demographic and clinical characteristics, refractory GERDwas
associated with an additional $7,089 (SD$7,705) in total costs and $845 (SD$111)
in GERD-related costs. CONCLUSIONS: Refractory GERD is a common disease that
may be associatedwith increasedmedical resource utilization and associated cost.
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COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL
HEALTHCARE COSTS AMONG INDIVIDUALS WITH INFLAMMATORY BOWEL
DISEASE AND FIVE MOST PREVALENT CHRONIC DISEASES
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USA, 3University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Inflammatory bowel disease (IBD) affects 1-1.4 million people in the
United States. IBD affects people during their economically productive adult lives
and can have potential economic impact of IBD on productivity loss in the work-
force.We compared risk, absenteeism, andmedical/pharmacy costs for employees
with IBD and fivemost prevalent chronic conditions.METHODS:Health-risk infor-
mation and self-reported illness days using health-risk assessment (HRA) data
were examined and direct Healthcare costs (medical and pharmacy) using claims
data for employees, retirees, and their adult dependents of a large self-insured
employer were compared from 2002-2006 among individuals with IBD and five
most prevalent chronic conditions; asthma, coronary artery disease/congestive
heart failure (CAD/CHF), diabetes, hypertension, chronic obstructive pulmonary
disease (COPD). RESULTS: 44 individuals with IBD were identified. The IBD cohort
had moderate health-risk score (2.6/5) which was comparable to individuals with
asthma (2.8/5), CHF (2.9), hypertension (2.6) and lower than diabetes (3.2/5) and
COPD (3.4/5). Whereas, higher proportion (31.8%) of individuals with IBD had 5
illness days per year as compared with individuals with asthma (31.8%), CAD/CHF
(25.9%), hypertension (20.4%), diabetes (28.4%), and COPD (33%). Annual direct
healthcare costs were higher for individuals with IBD ($24,911) as compared to
individuals CAD/CHF ($22,916), and hypertension ($18,632), and lower as compared
to individuals with asthma ($25,814), diabetes ($28,035), and COPD ($38,839).
CONCLUSIONS: Individuals with IBD have similar health-risks but higher illness
days, and direct healthcare costs as compared to the individuals with five most
prevalent chronic conditions. IBD is a high costs and lost productivity driver for
employers. Population health based programs that engage employees in appropri-
ately managing their chronic conditions can help employers reduce health-risks,
improve productivity, and may help reduce healthcare costs as well.
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COMPARISON OF DIRECT MEDICAL COSTS AND SERVICES BY POINT OF
SERVICE AND PRESCRIPTION COST FOR PERSONS WITH HEPATITIS-C WITH
AND WITHOUT TREATMENT
Brook RA1, Kleinman NL2, Smeeding J3
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 3JeSTARx
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OBJECTIVES: To compare the direct medical costs and services by point of service
(PoS) and the prescription drug (Rx) costs and services for persons with Hepatitis-C
(HCV) who are treated (HCV-Tx) and not-treated (HCV-noTx). METHODS: A retro-
spective analysis using the HCMS Research Reference database, which represents
multiple US-based employers and contains employee data from 2001-2Q2007. This
analysis compared the annual direct medical costs and services for healthcare by
PoS, and Rx costs and services for HCV employees with and without Tx. ICD-9
Codes were used to identify employees with HCV. All subjects were required to
have1 month of eligibility. The first ribavirin, interferon or peginterferon Rx was
the HCV-Tx cohort’s index date. The HCV-noTx cohort was assigned the average
index date (by company) of the HCV-Tx cohort. Two-part regression models were
used to compare the cohorts adjusting for demographics, job-related variables,
eligibilitymonths, and Charlson Comorbidity Index. PoS Locations include: doctors
office (MD), inpatient hospital (IN), outpatient hospital or clinic (OUT), emergency
department (ED), laboratory (LAB), and other. Annual Rx costs and services were
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